New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
07:30 EDTSYNSynthetic reports preclinical data to support clinical development of mAb
Synthetic Biologics announced positive preclinical research findings for SYN-005, the company's proprietary monoclonal antibody, or mAb, combination therapy for treating Pertussis. In the second pertussis study in particular, SYN-005 was associated with favorable decreases in white blood cell counts within two days and the achievement of nearly normal levels within one week. Based on positive non-human primate and murine model findings, Synthetic Biologics has filed an additional patent application around pertussis antibodies, intends to move into cGMP manufacturing of SYN-005, and intends to file an Investigational New Drug application to support a Phase I clinical trial expected to initiate during the first half of 2015. The Company also intends to request an Orphan Drug designation for SYN-005 for the treatment of Pertussis.
News For SYN From The Last 14 Days
Check below for free stories on SYN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 12, 2014
13:30 EDTSYNSynthetic Biologics confirms receipt of orphan drug designation for SYN-005
Subscribe for More Information
10:03 EDTSYNSynthetic Biologics treatment of Bordetella pertussis granted orphan status
Reference Link
07:00 EDTSYNSynthetic Biologics to host investor day
Investor Day to be held on September 16 at 9 am. Webcast Link
September 11, 2014
07:49 EDTSYNSynthetic Biologics to host conference call
Subscribe for More Information
September 10, 2014
07:09 EDTSYNAmericas Committee for Treatment & Research in MS to hold a meeting
Subscribe for More Information
September 7, 2014
17:11 EDTSYNSynthetic Biologics highlights new data from C. difficile program
Synthetic Biologics announced preclinical data that further validate the company's novel approach to preventing Clostridium difficile,C. difficile. The U.S. Centers for Disease Control has identified C. difficile as an "urgent public health threat," and it has surpassed MRSA as the number one hospital-acquired infection in the United States. The data were highlighted on September 6 at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, in Washington, D.C.
September 2, 2014
07:36 EDTSYNSynthetic Biologics announces positive results from study of SYN-004
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use